ANTIPAF – AFNET 2

Title

ANTIPAF – AFNET 2 Trial:
A randomized controlled clinical trial to investigate the efficacy of Olmesartane (Angiotensin II receptor blocker) to prevent paroxysmal atrial fibrillation

Coordinating Investigator

Prof. Andreas Goette, Paderborn

Overall Responsibility

Kompetenznetz Vorhofflimmern - Competence Network on Atrial Fibrillation

Registration

http://clinicaltrials.gov/show/NCT00098137

Current Status

Completed

Funding:

German Federal Ministry of Education and Research

Publications

Goette A, Schön N, Kirchhof P, Breithardt G, Fetsch T, Häusler KG, Klein HU, Steinbeck G, Wegscheider K, Meinertz T. Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF)-Trial. Circ Arrhythm Electrophysiol. 2012; 5;43-51. DOI:10.1161/CIRCEP.111.965178

von Eisenhart Rothe A, Bielitzer M, Meinertz T, Limbourg T, Ladwig KH, Goette A. Predictors of discordance between physicians' and patients' appraisals of health-related quality of life in atrial fibrillation patients: Findings from the Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation Trial. Am Heart J. 2013 Sep;166(3):589-596.e1. doi: 10.1016/j.ahj.2013.05.020.